98%
921
2 minutes
20
Background: Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) results from maternal platelet alloimmunization against paternal antigens inherited by the fetus, most often due to the Human Platelet Antigen (HPA)-1 system in Caucasians. We investigated in 2023, a 30-year-old Caucasian woman Gravida 2 Para 1 who gave birth at 35 weeks of gestation to a male (body weight 2210 g) without signs of bleeding. A severe thrombocytopenia (platelet count at 3 G/L) was discovered incidentally a few hours after delivery in the context of the management of a respiratory distress. The newborn recovered after one platelet concentrate transfusion and normalized his platelet count at Day 5.
Study Design And Methods: FNAIT investigation was performed according to guideline recommendations. Platelet genotyping was carried out by multiplex PCR. Maternal serological investigation included Monoclonal Antibody-specific Immobilization of Platelet Antigens method (MAIPA) and Luminex technology.
Results: Parental and newborn genotyping pointed out an HPA-4 incompatibility between the mother and the newborn and the father. Serological investigation revealed an anti-HPA-4b alloantibody confirming the diagnosis of neonatal alloimmune thrombocytopenia.
Conclusion: We described the third case of anti-HPA-4b alloantibody discovered in a Caucasian mother. This case strengthens the need for reference laboratory to genotype a panel of HPA alleles reflecting local genetic population diversity and for crossmatch of maternal serum with fresh paternal platelets in clinical suspected cases of neonatal alloimmune thrombocytopenia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/trf.17863 | DOI Listing |
Br J Haematol
September 2025
Department of Clinical Haematology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
To illustrate the challenges in the management of women with Glanzmann thrombasthenia (GT) planning a pregnancy, we conducted a literature review and present a case series of eight women giving detailed descriptions of reproductive health problems, platelet alloimmunisation, treatment to prevent post-partum haemorrhage and neonatal outcomes. ART, assisted reproductive therapy; PPH, post-partum haemorrhage; rFVIIa, recombinant activated factor VII.
View Article and Find Full Text PDFTransfus Clin Biol
September 2025
Department of Obstetrics & Gynecology, All India Institute of Medical Sciences, Jodhpur, Rajasthan. Electronic address:
Background: Red-cell alloimmunisation is a preventable driver of haemolytic disease of the fetus and newborn, yet most risk scores rely on single-parameter thresholds and overlook clinically important heterogeneity.
Objective: To uncover latent phenotypes among sensitised pregnancies by clustering routinely collected clinical and immunohaematologic variables.
Methods: We retrospectively analysed 2084 antenatal records (2020 - 2021).
Blood Transfus
August 2025
EFS BloodCenter of Brittany, HLA-HPA Laboratory, Rennes, France.
Background: Non-invasive fetal HPA typing is a valuable tool to identify the pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Different approaches have been developed, mainly based on real-time PCR and droplet digital-PCR. Those methods have a limited ability to multiplex and require replicates due to the contamination risk.
View Article and Find Full Text PDFNeoreviews
September 2025
Department of Obstetrics and Gynecology, Endeavor Health, Evanston Hospital, Evanston, Illinois.
Antibodies (Basel)
August 2025
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Antibody-mediated autoimmune diseases are common, can involve any organ system, and pose a large burden for patients and healthcare systems. Most antibody-mediated diseases are mediated by IgG antibodies. Selective targeting of pathogenic antibodies is an attractive treatment option which has already proven to be effective in antibody-positive generalized myasthenia gravis, maternal-fetal alloimmune cytopenias, and immune thrombocytopenic purpura.
View Article and Find Full Text PDF